HELLO CHINA

INDUSTRY CLUSTER · Biomedicine

Weihai Medical Devices

Weihai brings medical-polymer consumables, interventional devices and medical instruments into one industrial environment. City figures combine pharmaceuticals and devices, while High-tech Zone projects and regulatory records identify specific products and firms.

Formation and regional foundations

Figures published in 2025 contain separate parent and subset relationships for producers and innovation platforms. Research plans, proposed support, environmental lists and Korea trade reporting add technical, regulatory and market perspectives.

Weihai’s medical-device strengths span materials, consumables, intervention and instrument manufacturing. Combined city measures show scale, while company projects reveal technical direction.

Core geography: Weihai medical-device belt across the city and High-tech Zone

Weihai medical-device nodes

High-tech Zone product lines within the city

Project, regulatory and trade records each describe one company condition and are not interchangeable.

  • Weihai medical-device overview — Combined-chain figures provide citywide scale.
  • Medical polymers and consumables — Materials research connects infusion and implant uses.
  • Interventional devices — Vascular products connect project and regulatory records.
  • Medical-instrument manufacturing — Instrument classification broadens the device picture.
  • Weigao Medical Polymer — Its irradiation-resistant polypropylene targets medical devices.
  • JW Medical — The proposed project focuses on interventional devices.
  • Dazheng Medical Device — The ecology list confirms instrument manufacturing.

01 · Combined chain versus device scope

Two enterprise counts answer different questions.

The Weihai scale snapshot dated 29 July 2025 counts pharmaceuticals and medical devices within one combined industry chain. Producer, above-scale-enterprise, output and innovation measures therefore describe that wider chain and cannot be rewritten as figures for medical devices alone. At company level, registered products, production licences and actual sites must still be examined separately.

The 216 producers form the parent population for the combined chain, and the 75 above-scale enterprises are already included within it.

Combined-chain scale, device registration, innovation platforms and Korea trade answer four different questions.

  • Device firms cannot replace the combined total.

02 · Two parent-and-subset pairs

Firms and platforms cannot be combined.

The municipal market-regulator release records 216 pharmaceutical and medical-device production enterprises in Weihai at the release date, including 75 above-scale enterprises.

Adding 216 and 75 would count above-scale enterprises twice, while adding 104 and 39 would count higher-level platforms twice.

Updated figures must retain the parent-subset relationship for both companies and platforms.

  • Seventy-five sits within the 216 total.

03 · Weigao’s medical-polymer direction

A research plan links materials with devices.

An official High-tech Zone release identifies Shandong Weigao Group Medical Polymer Co., Ltd. and its 2025 project on key technologies and application demonstration for irradiation-resistant medical polypropylene materials and devices.

Entry into a provincial research plan marks staged support, not completed research or mass production.

Progress on irradiation-resistant polypropylene turns on later acceptance, device application and production scale-up.

  • Project approval is not mass production.

04 · JW Medical’s interventional project

Proposed support awaits a final outcome.

Shandong JW Medical Products Co., Ltd. appears in Weihai market-regulator coverage of the pharmaceutical and medical-device chain, where its product direction is associated with vascular-interventional devices. A proposed advanced-manufacturing support project and environmental-management information add project and local-regulation context. Together they locate the company within the industry, but production and sale of a specific device still depend on registration and licensing.

Proposed support records only the policy-procedure stage shown in 2025. It does not mean that funds were paid, a medical device was registered or a production line entered service. Project progress should therefore separate the final funding outcome, construction or equipment acceptance, device registration and production licensing, and each milestone must point to the same project and legal entity.

JW Medical’s position emerges from its intervention products, proposed project and ecology classification.

  • A project list is not device registration.

05 · Dazheng’s instrument classification

The ecology list provides industry and place.

The Weihai 2024 environmental-enforcement positive list places Shandong Dazheng Medical Device Co., Ltd. in the High-tech Zone and classifies it under medical instruments and device manufacturing. That classification records its local and industrial position for environmental oversight in that year; it is not a permanent compliance guarantee. Understanding its instruments still requires current registrations, production address, licence scope and quality system.

A positive-list regulatory context is not permanent compliance, product registration, quality certification, or an honour.

The ecology list gives Dazheng’s location and manufacturing class, while cluster reporting adds the High-tech Zone setting.

  • Regulatory classification is not a quality award.

06 · High-tech Zone and Korea trade

Park clustering and trade counts have distinct scopes.

The High-tech Zone and its medical-device and biopharmaceutical park form district and park contexts within Weihai rather than the geography of the four city measures.

The commerce report's 182 filed or registered producers use a device-only scope, including 104 enterprises trading medical devices with Korea.

Korea cooperation uses a device-only scope and should not be added to the combined chain or platform totals.

  • Trading firms use a device-only scope.

07 · Three firms, three product families

Materials, intervention and instruments stay distinct.

Weigao’s published project focuses on radiation-resistant medical polypropylene and device applications.

JW Medical is associated with vascular intervention and a proposed 2025 support project.

Dazheng is classified as medical-instrument and device manufacturing in the ecology list.

  • Shared location does not imply supply.

08 · Start with registrations and actual products

Confirm products and production sites first.

A route from Weigao materials through JW intervention to Dazheng instruments reveals three manufacturing logics.

Research plans, proposed support and ecology regulation describe technology, policy and management separately.

A Weihai medical-device visit can follow three routes—materials and disposables, vascular-interventional products and medical instruments—because registration, clean manufacturing and validation differ. Before contacting a firm, confirm the exact registered product, actual production site and project stage, then ask which product and period any Korea cooperation concerns. On site, trace one lot through material, production, inspection and release rather than using chain scale as a substitute for product responsibility.

  • Ask separately about projects, capacity and trade.

Sources and reading notes

Combined-chain and device-only statistics remain separate, and project status follows its dated announcement.

  • Pharmaceutical and medical-device producers at the release date: 216 pharmaceutical and medical-device production enterprises (Weihai combined pharmaceutical and medical-device chain at the 2025-07-29 release date).
  • Above-scale enterprises within the combined chain: 75 above-scale enterprises (Subset of the 216 Weihai combined-chain production enterprises at the 2025-07-29 release date).
  • A total of 104 innovation platforms had been established across Weihai’s combined pharmaceutical and medical-device chain by the 2025-07-29 release date.
  • Provincial-level or higher platforms within the platform set: 39 provincial-level or higher innovation platforms (Subset of the 104 combined-chain innovation platforms at the 2025-07-29 release date).

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.